Literature DB >> 1977782

Pharmacology of antihistamines.

J K Woodward1.   

Abstract

Unlike the classic antihistamines, the new H1-receptor antagonists do not block cholinergic or central H1 receptors and thus do not produce the side effects, such as sedation, impaired psychomotor performance, and excessive mucosal drying, that are commonly associated with the older agents. Important pharmacokinetic and pharmacodynamic differences that exist among this class of antihistamines translate into varying pharmacologic effectiveness. Terfenadine, loratadine, and cetirizine are all rapidly absorbed in healthy and allergic volunteers (peak plasma levels, 2 to 5 hours); astemizole, however, has an initial distribution phase of 2 to 3 days. Further, astemizole has the longest time to relief of symptoms in this class; histamine wheal inhibition is not apparent until the second day of 10 mg dosing and does not peak for 9 to 12 days. In comparison, terfenadine's antihistaminic action peaks at 3 to 4 hours, loratadine's at 4 to 6 hours, and cetirizine's at 4 to 10 hours. However, whereas the recommended dose of loratadine (10 mg) confers 50% wheal inhibition, 60 mg terfenadine produces an 85% to 90% inhibition. In addition, loratadine and cetrizine have apparent dose-related sedative effects.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1977782     DOI: 10.1016/s0091-6749(05)80224-6

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  6 in total

1.  WHO guidelines for treatment of tuberculosis: the missing links.

Authors:  Muhammad Atif; Syed Azhar Syed Sulaiman; Asrul Akmal Shafie; Irfhan Ali; Mohamed Azmi Hassali; Fahad Saleem
Journal:  Int J Clin Pharm       Date:  2012-06-16

2.  Second-generation antihistamines: a comparative review.

Authors:  J W Slater; A D Zechnich; D G Haxby
Journal:  Drugs       Date:  1999-01       Impact factor: 9.546

3.  Design of a suitable formulation of FK613, a novel antiallergic agent, based on its pharmacokinetic and pharmacodynamic properties in healthy subjects.

Authors:  T Uematsu; S Nagashima; H Inaba; T Kajiho; H Kageyama; A Sugiyama; M Nakashima
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

4.  The effect of intracerebroventricular injection of histamine in visceral nociception induced by acetic acid in rats.

Authors:  Ali Zanboori; Esmaeal Tamaddonfard; Ali Mojtahedin
Journal:  Indian J Pharmacol       Date:  2010-10       Impact factor: 1.200

Review 5.  Loratadine. A review of recent findings in pharmacology, pharmacokinetics, efficacy, and safety, with a look at its use in combination with pseudoephedrine.

Authors:  I J Roman; M R Danzig
Journal:  Clin Rev Allergy       Date:  1993

6.  Histamine as an intermediate growth factor in genesis of gastric ECLomas associated with hypergastrinemia in mastomys.

Authors:  I M Modlin; R R Kumar; C J Soroka; H Ahlman; O Nilsson; J R Goldenring
Journal:  Dig Dis Sci       Date:  1994-07       Impact factor: 3.199

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.